Brief: Mineralys Therapeutics Announces Positive Topline Results From Launch-HTN And Advance-HTN Pivotal Trials Of Lorundrostat For The Treatment Of Uncontrolled Or Resistant Hypertension
10/03/2025 11:02
March 10 (Reuters) - Mineralys Therapeutics Inc MLYS.O: MINERALYS THERAPEUTICS ANNOUNCES POSITIVE TOPLINE RESULTS FROM LAUNCH-HTN AND ADVANCE-HTN PIVOTAL TRIALS OF LORUNDROSTAT FOR THE TREATMENT OF UNCONTROLLED OR RESISTANT HYPERTENSION MINERALYS THERAPEUTICS INC: ADVANCE-HTN MET ITS PRIMARY ENDPOINT MINERALYS THERAPEUTICS INC: LAUNCH-HTN MET ITS PRIMARY ENDPOINT MINERALYS THERAPEUTICS INC: LAUNCH-HTN MET ITS PRIMARY ENDPOINT MINERALYS THERAPEUTICS INC: LORUNDROSTAT DEMONSTRATED A FAVORABLE SAFETY AND TOLERABILITY PROFILE IN BOTH PIVOTAL TRIALS Source text: ID:nGNX7jhzJS Further company coverage: MLYS.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mineralys Therapeutics
See all newsBrief: Mineralys Therapeutics Expands Its Board Of Directors With The Appointments Of Kristine Peterson And Lonnel Coats
Mineralys Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Brief: Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(C)(4)
U.S. STOCKS ON THE MOVE-Medtronic, Macy's, USA Rare Earth
U.S. STOCKS ON THE MOVE-USA Rare Earth, MiniMed, Rent the Runway